Synairgen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Synairgen prognostiziert ein Gewinnwachstum at 40.6% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 40.6% pro Jahr.

Wichtige Informationen

46.6%

Wachstumsrate der Gewinne

46.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	35.9%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	-66.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Dec 09

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Feb 06

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Oct 21

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Mar 29

How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

Dec 14

Gewinn- und Umsatzwachstumsprognosen

AIM:SNG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2023	N/A	-8	-8	-8	N/A
9/30/2023	N/A	-9	-6	-6	N/A
6/30/2023	N/A	-10	-4	-4	N/A
3/31/2023	N/A	-14	-9	-9	N/A
12/31/2022	N/A	-18	-14	-14	N/A
9/30/2022	N/A	-23	-21	-21	N/A
6/30/2022	N/A	-28	-28	-28	N/A
3/31/2022	N/A	-38	-35	-35	N/A
12/31/2021	N/A	-49	-41	-41	N/A
9/30/2021	N/A	-46	-44	-44	N/A
6/30/2021	N/A	-43	-48	-48	N/A
3/31/2021	N/A	-28	-36	-36	N/A
12/31/2020	N/A	-14	-24	-24	N/A
9/30/2020	N/A	-10	-15	-15	N/A
6/30/2020	N/A	-6	-6	-6	N/A
3/31/2020	N/A	-5	-4	-4	N/A
12/31/2019	N/A	-4	-3	-3	N/A
9/30/2019	0	-4	-4	-4	N/A
6/30/2019	0	-4	-4	-4	N/A
3/31/2019	0	-3	-4	-4	N/A
12/31/2018	0	-3	-4	-4	N/A
9/30/2018	3	-1	-1	-1	N/A
6/30/2018	5	2	2	2	N/A
3/31/2018	5	2	2	2	N/A
12/31/2017	5	2	2	2	N/A
9/30/2017	3	0	N/A	-1	N/A
6/30/2017	0	-3	N/A	-3	N/A
3/31/2017	0	-3	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A
9/30/2016	N/A	-3	N/A	-3	N/A
6/30/2016	N/A	-3	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-2	N/A
9/30/2015	0	-2	N/A	-2	N/A
6/30/2015	0	-2	N/A	-2	N/A
3/31/2015	2	0	N/A	0	N/A
12/31/2014	4	1	N/A	2	N/A
9/30/2014	4	1	N/A	2	N/A
6/30/2014	4	1	N/A	3	N/A
3/31/2014	2	-1	N/A	0	N/A
12/31/2013	N/A	-2	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SNG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SNG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SNG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SNG schneller wachsen werden als der Markt von UK.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von SNG schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SNG wird voraussichtlich in 3 Jahren unrentabel sein.

Synairgen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to UK£2.20

Price target decreased to UK£2.20

Recent updates

Synairgen plc, Annual General Meeting, Oct 10, 2024

New minor risk - Financial data availability

Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024

New major risk - Market cap size

New major risk - Share price stability

New minor risk - Financial data availability

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

New major risk - Share price stability

Synairgen plc Announces Executive Changes

Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer

Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation

Synairgen plc, Annual General Meeting, Jun 29, 2023

Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research

Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee

Price target decreased to UK£2.20

No independent directors

Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health (Nih)/ Aids Clinical Trials Group (Actg)-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19

Synairgen plc Announces Changes to Its Board

Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate

Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients

Synairgen plc Announces Collaboration on Universal Trial

Synairgen plc, Annual General Meeting, Jun 30, 2022

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

Less than half of directors are independent

Synairgen plc to Report Fiscal Year 2021 Results on May 25, 2022

Synairgen plc Provides Update on SNG001 in the ACTIV-2 Phase 3 Trial for COVID-19 and on SNG001 Activity Against Delta and Omicron Variants

Price target decreased to UK£2.20

Synairgen plc Announces Topline Results from Phase 3 SPRINTER trial of SNG001

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Synairgen plc Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Synairgen plc Announces Results of in Vitro Studies

Synairgen Announces Data from Home Cohort of SG016 Phase II Trial of Inhaled Interferon Beta in COVID-19 Patients and Encouraging Combined Data for Whole SG016 Trial

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Synairgen Announces Dosing Has Commenced with Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients

New 90-day high: UK£1.90

New 90-day high: UK£1.88

Synairgen Announces Inclusion of Its Inhaled Interferon Beta Treatment in US NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc Announces Completion of Recruitment into Its Phase Ii Home-Based Covid-19 Study of Inhaled Interferon Beta

Synairgen Announces Commencement of Dosing in Its International Phase III Study of Inhaled Interferon Beta in Hospitalised COVID-19 Patients

Synairgen plc Provides COVID-19 Clinical Programme Update

How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

New 90-day low: UK£0.77

Clinigen Group plc Signs Managed Access Program Agreement with Synairgen plc

New 90-day high - UK£2.32

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken